Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 7.8% – Should You Sell?

On January 2, 2025, shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) experienced a decline of 7.8%. The stock reached a low of $0.33 before closing at the same price, following a previous close of $0.36. During midday trading, about 39,393,920 shares were exchanged, which represents a 28% increase compared to the average daily trading volume of 30,856,506 shares.

Analysts Set New Price Targets

In a separate development, StockNews.com initiated coverage of Tonix Pharmaceuticals with a “hold” rating for the stock.

Tonix Pharmaceuticals Stock Performance

Tonix Pharmaceuticals holds a quick ratio of 2.81 and a current ratio of 3.33, indicating a solid liquidity position. Additionally, the company has a modest debt-to-equity ratio of 0.07. With a market capitalization of $61.64 million, the stock displays a negative PE ratio of -0.01 and a beta of 2.23, suggesting higher volatility compared to the overall market. The company's stock has a 50-day simple moving average of $0.23 and a 200-day simple moving average of $0.37.

In its latest earnings announcement on November 12, 2023, Tonix Pharmaceuticals reported an EPS of ($0.23), which surpassed analysts' expectations who anticipated an EPS of ($2.03). The company generated $2.82 million in revenue, exceeding the projected $2.63 million. However, the firm continues to face challenges with a net margin of -1,197.86% and a return on equity of -163.95%. Analysts forecast that Tonix Pharmaceuticals will report an EPS of -17.63 for the ongoing fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on the research, development, commercialization, and licensing of therapies aimed at treating and preventing human diseases. The company is known for marketing Zembrace SymTouch and Tosymra, both of which are indicated for the treatment of acute migraine with or without aura in adults.

Tonix, Pharmaceuticals, Stocks